Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : BMO Capital Adjusts Gilead Sciences' Price Target to $72 From $67, Maintains Market Perform Rating

07/30/2021 | 11:21am EDT


ę MT Newswires 2021
All news about GILEAD SCIENCES, INC.
09/23GILEAD SCIENCES : Veklury (Remdesivir) Significantly Reduced Risk of Hospitalization in Hi..
AQ
09/22GILEAD SCIENCES : Veklury Lowers Hospitalization Risk in COVID-19 Patients in Phase 3 Stud..
MT
09/22BROOKLYN IMMUNOTHERAPEUTICS : Names Roger Sidhu Chief Medical Officer
MT
09/22GILEAD SCIENCES : Veklury« (Remdesivir) Significantly Reduced Risk of Hospitalization in H..
BU
09/22Gilead Sciences, Inc. Announces Positive Results from A Phase 3 Randomized, Double-Blin..
CI
09/20GILEAD SCIENCES : to Present Latest Antiviral Research Data Addressing Urgent Global Needs..
BU
09/20Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infe..
CI
09/17GILEAD SCIENCES : Trodelvy Significantly Improved Quality of Life Over Standard of Care in..
AQ
09/17GILEAD SCIENCES : New Data Demonstrate Trodelvy Survival Benefit in Metastatic Triple-Nega..
AQ
09/17Gritstone bio, Inc. announced that it has received $55 million in funding from Frazier ..
CI
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 25 003 M - -
Net income 2021 6 530 M - -
Net Debt 2021 23 112 M - -
P/E ratio 2021 14,2x
Yield 2021 3,95%
Capitalization 89 886 M 89 886 M -
EV / Sales 2021 4,52x
EV / Sales 2022 4,46x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 71,69 $
Average target price 76,42 $
Spread / Average Target 6,60%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.23.05%89 886
BIONTECH SE333.01%85 255
WUXI APPTEC CO., LTD.34.39%68 592
REGENERON PHARMACEUTICALS33.82%67 216
VERTEX PHARMACEUTICALS-21.68%48 018
BEIGENE, LTD.49.16%35 859